JPMorgan analyst Anupam Rama raised the firm’s price target on Replimune to $17 from $14 and keeps an Overweight rating on the shares.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REPL:
- Replimune presents primary analysis data from IGNYTE clinical trial
- Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024
- Replimune completes pre-BLA meeting with FDA for RP1
- Replimune Announces Positive Pre-BLA Meeting with FDA and Confirms BLA Submission On Track for 2H 2024
- Replimune appoints Balachandran to board of directors